BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33628621)

  • 1. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors.
    Patrinely JR; McGuigan B; Chandra S; Fenton SE; Chowdhary A; Kennedy LB; Mooradian MJ; Palmeri M; Portal D; Horst SN; Scoville EA; Long GV; Shi C; Mehnert JM; Sullivan RJ; Salama AK; Sosman JA; Menzies AM; Johnson DB
    Oncoimmunology; 2021 Feb; 10(1):1875639. PubMed ID: 33628621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
    Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations.
    Park BC; Narayanan S; Gavraldis A; Ye F; Fan R; Sullivan RJ; Boland G; Reynolds KL; Balko JM; Carlino MS; Long GV; Zubiri L; Menzies AM; Johnson DB
    Oncoimmunology; 2023; 12(1):2188719. PubMed ID: 36926262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma.
    Shah P; Punekar SR; Pavlick AC
    Melanoma Res; 2021 Jun; 31(3):242-248. PubMed ID: 33741813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal.
    Gauci ML; Baroudjian B; Bédérède U; Zeboulon C; Delyon J; Allayous C; Madelaine I; Eftekhari P; Resche-Rigon M; Poté N; Paradis V; Durand F; Lebbé C; Roux O; Bouattour M;
    Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101491. PubMed ID: 32773362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study.
    Riveiro-Barciela M; Barreira-Díaz A; Callejo-Pérez A; Muñoz-Couselo E; Díaz-Mejía N; Díaz-González Á; Londoño MC; Salcedo MT; Buti M
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):732-740. PubMed ID: 35487453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer.
    Jacob JS; Dutra BE; Garcia-Rodriguez V; Panneerselvam K; Abraham FO; Zou F; Ma W; Grivas P; Thompson JA; Altan M; Oliva ICG; Zhang HC; Thomas AS; Wang Y
    J Natl Compr Canc Netw; 2021 Aug; 19(12):1415-1424. PubMed ID: 34348238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
    Foster CC; Couey MA; Kochanny SE; Khattri A; Acharya RK; Tan YC; Brisson RJ; Leidner RS; Seiwert TY
    Cancer; 2021 Dec; 127(24):4565-4573. PubMed ID: 34547103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
    Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
    Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.
    Kawahira M; Kanmura S; Mizuno K; Machida K; Ohtsuka T; Sato M; Enokida H; Yamashita M; Kanekura T; Arima S; Nakamura N; Sugiura T; Yoshimoto K; Kobayashi H; Ishitsuka K; Suzuki S; Ueno S; Ido A
    PLoS One; 2022; 17(4):e0267572. PubMed ID: 35482642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
    Siddiqui BA; Gheeya JS; Goswamy R; Bathala TK; Surasi DS; Gao J; Shah A; Campbell MT; Msaouel P; Goswami S; Wang J; Zurita AJ; Jonasch E; Corn PG; Aparicio AM; Siefker-Radtke AO; Sharma P; Subudhi SK; Tannir N
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
    Simonaggio A; Michot JM; Voisin AL; Le Pavec J; Collins M; Lallart A; Cengizalp G; Vozy A; Laparra A; Varga A; Hollebecque A; Champiat S; Marabelle A; Massard C; Lambotte O
    JAMA Oncol; 2019 Sep; 5(9):1310-1317. PubMed ID: 31169866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.